

Comparative Protein Structure Modeling and its Applications to Drug Discovery

Matthew Jacobson¹ and Andrej Sali^{1,2}

¹*Department of Pharmaceutical Chemistry, California Institute for Quantitative Biomedical Research, Mission Bay Genentech Hall, 600 16th Street, University of California, San Francisco, CA 94143-2240, USA*

²*Department of Biopharmaceutical Sciences, California Institute for Quantitative Biomedical Research, Mission Bay Genentech Hall, 600 16th Street, University of California, San Francisco, CA 94143-2240, USA*

Contents

1. Introduction	259
2. Fold assignment and sequence-structure alignment	261
3. Comparative model building	261
4. Loop modeling	262
5. Sidechain modeling	263
6. Comparative modeling by MODELLER	264
7. Physics-based approaches to comparative model construction and refinement	264
8. Accuracy of comparative models	266
9. Modeling on a genomic scale	266
10. Applications of comparative modeling to drug discovery	267
10.1. Comparative models vs experimental structures in virtual screening	267
10.2. Use of comparative models to obtain novel drug leads	268
10.3. Comparative models of kinases in virtual screening	269
10.4. GPCR comparative models for drug development	270
10.5. Other uses of comparative models in drug development	271
10.6. Future directions	272
11. Conclusions	273
References	273

1. INTRODUCTION

Homology or comparative protein structure modeling constructs a three-dimensional model of a given protein sequence based on its similarity to one or more known structures. In this perspective, we begin by describing the comparative modeling technique and the accuracy of the models. We then discuss the significant role that comparative prediction plays in drug discovery. We focus on virtual ligand screening against comparative models and illustrate the state-of-the-art by a number of specific examples.

The genome sequencing efforts are providing us with complete genetic blueprints for hundreds of organisms, including humans. We are now faced with describing,

controlling, and modifying the functions of proteins encoded by these genomes. This task is generally facilitated by protein three-dimensional structures [1], which are best determined by experimental methods such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy. Despite significant advances in these techniques, many protein sequences are not easily accessible to structure determination by experiment. Over the last two years, the number of sequences in the comprehensive public sequence databases, such as SwissProt/TrEMBL [2] and GenPept [3], increased by a factor of 2.3 from 522,959 to 1,215,803 on 26 April 2004. In contrast, despite structural genomics, the number of experimentally determined structures deposited in the Protein Data Bank (PDB) increased by only a factor of 1.4 over the same period, from 16,612 to 23,793 [4]. Thus, the gap between the numbers of known sequences and structures continues to grow.

Protein structure prediction methods attempt to bridge this gap [5]. The first class of protein structure prediction methods, including threading and comparative modeling, rely on detectable similarity spanning most of the modeled sequence and at least one known structure [6]. The second class of methods, *de novo* or *ab initio* methods, predict the structure from sequence alone, without relying on similarity at the fold level between the modeled sequence and any of the known structures [7]. Despite progress in *ab initio* protein structure prediction [7,8], comparative modeling remains the most reliable method to predict the 3D structure of a protein with an accuracy that can be comparable to a low-resolution, experimentally determined structure [6].

Comparative modeling is carried out in four sequential steps: finding known structures (templates) related to the sequence to be modeled (target), aligning the target sequence with the templates, building the model, and assessing the model. Therefore, comparative modeling is only applicable when the target sequence is detectably related to a known protein structure. Using automated comparative modeling, the fraction of sequences with comparative models for at least one domain remained at $\sim 57\%$ over the last two years [9].

A number of servers for automated comparative modeling are available (http://salilab.org/bioinformatics_resources.shtml). Automation makes comparative modeling accessible to both experts and the non-specialists alike. Many of the servers are tested at the bi-annual CAFASP meetings and continually by the LiveBench and EVA [10–14] web servers for assessment of automated structure prediction methods. However, in spite of automation, manual intervention is generally still needed to maximize the accuracy of the models.

Comparative modeling will benefit from structural genomics [15]. Structural genomics aims to structurally characterize most protein sequences by an efficient combination of experiment and prediction [16,17]. This aim will be achieved by careful selection of target proteins and their structure determination by X-ray crystallography or NMR spectroscopy. There are a variety of target selection schemes, ranging from focusing on only novel folds to selecting all proteins in a model genome [1]. A model-centric view requires that targets be selected such that most of the remaining sequences can be modeled with useful accuracy by comparative modeling. Even with structural genomics, the structure of most proteins will be modeled, not determined by experiment. As discussed below, the accuracy of comparative models, and correspondingly the variety of their applications, decreases sharply below the 30% sequence identity cutoff, mainly as a result of a rapid increase in alignment errors. Thus, structural genomics aims

to determine protein structures such that most of the remaining sequences are related to at least one known structure at higher than 30% sequence identity [1,15,17]. It was recently estimated that this cutoff requires a minimum of 16,000 structures to cover 90% of all protein domain families, including those of membrane proteins [17]. These 16,000 structures will allow the modeling of a very much larger number of proteins. For example, the New York Structural Genomics Research Consortium measured the impact of its structures by documenting the number and quality of the corresponding models for detectably related proteins in the non-redundant sequence database. For each new structure, on average ~ 100 protein sequences without any prior structural characterization could be modeled at least at the fold level [9]. This large leverage of structure determination by protein structure modeling illustrates and justifies the premise of structural genomics.

We begin by reviewing the methods needed for each of the four steps of comparative modeling. While we only briefly touch on fold assignment, sequence-structure alignment, and model assessment, we elaborate on model building; we emphasize the modeling of loops and sidechains, because of their importance in ligand docking and rational drug discovery. We continue by describing MODBASE, a comprehensive database of comparative models. Next, we describe the role of comparative modeling in drug discovery, focusing on ligand docking against comparative models. We compare successes of docking against models and x-ray structures, and illustrate the computational docking against models with a number of examples, including kinases and G-protein coupled receptors.

2. FOLD ASSIGNMENT AND SEQUENCE-STRUCTURE ALIGNMENT

The templates for modeling may be found by pairwise sequence alignment methods, such as BLAST and FASTA, profile-sequence alignment methods, such as PSI-BLAST, profile-profile alignment methods, such as SALIGN, Hidden Markov Models, such as SAM-T02, and sequence-structure threading methods that can sometimes reveal more distant relationships than purely sequence-based methods [18–23]. Threading methods assign the fold by threading the sequence through each of the structures in a library of all known folds; each sequence-structure alignment is assessed by the energy of a corresponding coarse model, not by sequence similarity as in sequence comparison methods. Recently, the accuracy of aligning a sequence to a remotely related protein structure has been improved by a genetic algorithm protocol that iterates through alignment, model building, and model assessment [24].

3. COMPARATIVE MODEL BUILDING

Comparative protein structure prediction produces an all-atom model of a sequence, based on its alignment to one or more related protein structures. Comparative model building includes either sequential or simultaneous modeling of the core of the protein, loops, and side-chains. In the original comparative approach, a model is constructed from

a few template core regions, and from loops and side-chains obtained from either aligned or unrelated structures [25–27]. Another family of comparative methods relies on approximate positions of conserved atoms from the templates to calculate the coordinates of other atoms [28]. A third group of methods uses either distance geometry or optimization techniques to satisfy spatial restraints obtained from the sequence-template alignment [29–31]. Next, we review a large variety of specialized methods that focus on the modeling of loops in a fixed environment of the rest of the protein and the modeling of sidechains on a fixed backbone.

4. LOOP MODELING

In comparative modeling, target sequences often have residues inserted relative to the template structures or have regions that are structurally different from the corresponding regions in the templates. Thus, no structural information about these segments can be extracted from the template structures. These regions frequently correspond to surface loops. Loops often play an important role in defining the functional specificity of a given protein, forming the active and binding sites. The accuracy of loop modeling can be a major factor determining the usefulness of comparative models in applications such as ligand docking. Loop modeling can be seen as a mini protein folding problem because the correct conformation of a given segment of a polypeptide chain has to be calculated mainly from the sequence of the segment itself. However, loops are generally too short to provide sufficient information about their local fold. Even identical decapeptides in different proteins do not always have the same conformation [32,33]. Some additional restraints are provided by the core anchor regions that span the loop and by the structure of the rest of a protein that cradles the loop. Although many loop modeling methods have been described, it is still challenging to model correctly and confidently loops longer than approximately 8–10 residues [34,35].

There are two main classes of loop modeling methods: (i) database search approaches that scan a database of all known protein structures to find segments fitting the anchor core regions [36,37]; (ii) conformational search approaches that rely on optimizing a scoring function [38–40]. There are also methods that combine these two approaches [41,42].

The database search approach to loop modeling is accurate and efficient when a database of specific loops is created to address the modeling of the same class of loops, such as β -hairpins [43], or loops on a specific fold, such as the hypervariable regions in the immunoglobulin fold [37,44]. There are attempts to classify loop conformations into more general categories, thus extending the applicability of the database search approach [45–47]. However, the database methods are limited because the number of possible conformations increases exponentially with the length of a loop. As a result, only loops up to 4–7 residues long have most of their conceivable conformations present in the database of known protein structures [48,49]. This limitation is made even worse by the requirement for an overlap of at least one residue between the database fragment and the anchor core regions, which means that modeling a five residue insertion requires at least a seven residue fragment from the database [50]. Despite the rapid growth of the database of known structures, it does not seem possible to cover most

of the conformations of a 9-residue segment in the foreseeable future. On the other hand, most of the insertions in a family of homologous proteins are shorter than 10–12 residues [34].

To overcome the limitations of the database search methods, conformational search methods were developed [38,39]. There are many such methods, exploiting different protein representations, objective functions, and optimization or enumeration algorithms. The search algorithms include the minimum perturbation method, molecular dynamics simulations, genetic algorithms, Monte Carlo and simulated annealing, multiple copy simultaneous search, self-consistent field optimization, and enumeration based on graph theory [41,51–59]. The accuracy of loop predictions can be further improved by clustering the sampled loop conformations and partially accounting for the entropic contribution to the free energy [60]. Another way to improve the accuracy of loop predictions is to consider the solvent effects. Improvements in implicit solvation models, such as the Generalized Born solvation model, motivated their use in loop modeling. The solvent contribution to the free energy can be added to the scoring function for optimization, or it can be used to rank the sampled loop conformations after they are generated with a scoring function that does not include the solvent terms [34,61–64].

5. SIDECCHAIN MODELING

Two simplifications are frequently applied in the modeling of sidechain conformations. First, amino acid residue replacements often leave the backbone structure almost unchanged [65], allowing us to fix the backbone during the search for the best sidechain conformations. Second, most sidechains in high-resolution crystallographic structures can be represented by a limited number of conformers that comply with stereochemical and energetic constraints [66]. This observation motivated Ponder and Richards to develop the first library of sidechain rotamers for the 17 types of residues with dihedral angle degrees of freedom in their sidechains, based on 10 high-resolution protein structures determined by X-ray crystallography [67]. Subsequently, a number of additional libraries have been derived [68–72].

Rotamers on a fixed backbone are often used when all the sidechains need to be modeled on a given backbone. This approach reduces the combinatorial explosion associated with a full conformational search of all the sidechains, and is applied by some comparative modeling [27] and protein design approaches [73]. However, ~15% of the sidechains can not be represented well by these libraries [74]. In addition, it has been shown that the accuracy of sidechain modeling on a fixed backbone decreases rapidly when the backbone errors are larger than 0.5 Å [75].

Earlier methods for sidechain modeling often put less emphasis on the energy or scoring function. The function was usually greatly simplified, and consisted of the empirical rotamer preferences and simple repulsion terms for non-bonded contacts [69]. Nevertheless, these approaches have been justified by their performance. For example, a method based on a rotamer library compared favorably with that based on a molecular mechanics force field, and new methods continue to be based on the rotamer library approach [72,76,77]. The various optimization approaches include a Monte Carlo simulation, simulated annealing, a combination of Monte Carlo and simulated annealing,

the dead-end elimination theorem, genetic algorithms, neural network with simulated annealing, mean field optimization, and combinatorial searches [69,78–86]. Several recent papers focused on the testing of more sophisticated potential functions for conformational search [86,87] and development of new scoring functions for side chain modeling [77,88], reporting higher accuracy than earlier studies.

6. COMPARATIVE MODELING BY MODELLER

MODELLER is a computer program for comparative protein structure modeling [30,34]. In the simplest case, the input is an alignment of a sequence to be modeled with the template structures, the atomic coordinates of the templates, and a short script file. MODELLER then automatically calculates a model containing all non-hydrogen atoms, without any user intervention and within minutes on a Pentium processor.

MODELLER implements comparative protein structure modeling by satisfaction of spatial restraints [30]. The spatial restraints include (i) homology-derived restraints on the distances and dihedral angles in the target sequence, extracted from its alignment with the template structures [30], (ii) stereochemical restraints such as bond length and bond angle preferences, obtained from the CHARMM-22 molecular mechanics force-field [89], (iii) statistical preferences for dihedral angles and non-bonded inter-atomic distances, obtained from a representative set of known protein structures [90], and (iv) optional manually curated restraints, such as those from NMR spectroscopy, rules of secondary structure packing, cross-linking experiments, fluorescence spectroscopy, image reconstruction from electron microscopy, site-directed mutagenesis, and intuition. The spatial restraints, expressed as probability density functions, are combined into an objective function that is optimized by a combination of conjugate gradients and molecular dynamics with simulated annealing. This model building procedure is similar to structure determination by NMR spectroscopy.

Apart from model building, MODELLER can perform additional auxiliary tasks, including alignment of two protein sequences or their profiles, multiple alignment of protein sequences and/or structures, calculation of phylogenetic trees, and *de novo* modeling of loops in protein structures [34].

7. PHYSICS-BASED APPROACHES TO COMPARATIVE MODEL CONSTRUCTION AND REFINEMENT

In principle, an accurate and efficient method for estimating the free energy of a given protein conformation could substantially improve the accuracy of comparative models. That is, an accurate energy function combined with efficient sampling could be used to refine initially constructed comparative models and thus decrease their RMS error, assuming that the native state represents the lowest free energy state. We suggest that accurate energy-based scoring may be particularly important for accurately reproducing the fine details (e.g., specific hydrogen bonding interactions) of protein active sites, which in turn will be critical for success of virtual screening using comparative models. Two key challenges confronting this approach are (i) efficient but accurate methods for

treating solvent (many methods have entirely ignored solvent or used low-accuracy but efficient distance-dependent dielectric representations); and (ii) the estimation of entropic contributions to free energy differences among states, which generally requires extensive sampling.

As discussed above, loop and sidechain prediction algorithms rely on scoring functions to guide the sampling, aiming to identify favorable conformations and reject unfavorable ones. These scoring functions typically do not explicitly attempt to estimate the free energy of a given conformation. Rather, most scoring functions have been based on statistical analyses of native protein structures encoded in the so-called potentials-of-mean-force, heuristic functional forms, or highly simplified energetic models (e.g., only van der Waals energy terms). Electrostatic interactions and, especially, the effect of solvent are infrequently used in such algorithms, largely due to their computational expense; a large number of conformations of a protein model must typically be scored during comparative model construction, and thus the scoring function must be rapid to compute.

Nonetheless, a number of groups have made efforts to use more sophisticated energetic scoring functions for comparative model construction and refinement. Recently, the convergence of increased computing power as well as accurate and efficient implicit solvent models (i.e., Poisson–Boltzmann and Generalized Born models) has bolstered these efforts. In the realm of loop modeling, there have been several groups reporting recent studies [62,91–93]; all four of these studies employed all-atom force fields and Generalized Born solvent models for scoring. An alternative recent approach is that of Hornak and Simmerling, which uses molecular dynamics methods [94]. Xiang and Honig developed a function that attempts to mimic the entropic contribution to free energy without rigorous sampling [72]. These studies have focused on reproducing loop conformations in native protein structures.

The problem of refining comparative models to improve accuracy is more challenging, and early attempts to use molecular dynamics or energy minimization in this context had mixed success, frequently increasing the RMS error of the models [95,96]. Nonetheless, physics-based energy functions, although certainly not perfect, have shown impressive abilities to distinguish native from non-native protein structures [61,97], suggesting that the model accuracy may be currently limited by incomplete sampling rather than the accuracy of the scoring function. A few recent reports about successful refinement of comparative models by restrained molecular dynamics [98,99] support this viewpoint.

A complete software package for physics-based comparative model construction and refinement has been developed [146]. The energy function employed is based on the OPLS all-atom force field and Surface Generalized Born solvent model with a non-polar estimator [100–103]. The sampling algorithms, which all use this energy function, include side chain and loop and helix prediction; the latter capability is novel and addresses the fact that corresponding helices in homologous proteins frequently adopt differing conformations, especially at relatively low sequence identity [64,87,104]. The loop prediction algorithm is, to our knowledge, the most accurate yet reported in the literature when tested by reconstructing hundreds of loops in native structures. Of particular relevance to virtual ligand screening against comparative models (as discussed below), the comparative model construction algorithm permits inclusion of co-factors and ligands as the model is built, which can help to improve accuracy of binding site conformations.

8. ACCURACY OF COMPARATIVE MODELS

The accuracy of the predicted model determines the information that can be extracted from it. Thus, estimating the accuracy of 3D protein models in the absence of the known structures is essential for interpreting them. The model can be evaluated as a whole as well as in the individual regions. There are many model evaluation programs and servers [147].

The accuracy of comparative modeling is related to the percentage sequence identity on which the model is based, correlating with the relationship between the structural and sequence similarities of two proteins [6,96,105]. High accuracy comparative models are generally based on more than 50% sequence identity to their templates. They tend to have approximately 1 Å RMS error for the main-chain atoms, which is comparable to the accuracy of a medium resolution NMR structure or a low-resolution X-ray structure. The errors are mostly mistakes in side-chain packing, small shifts or distortions of the core main-chain regions, and occasionally larger errors in loops. Medium accuracy comparative models are based on 30–50% sequence identity. They tend to have approximately 90% of the main-chain modeled with 1.5 Å RMS error. Errors in side-chain packing, core distortion, and loop modeling errors are more frequent, and there are occasional alignment mistakes [105]. Finally, low accuracy comparative models are based on less than 30% sequence identity. Alignment errors increase rapidly below 30% sequence identity and become the most significant source of errors in comparative models. In addition, when a model is based on an almost insignificant alignment to a known structure, it may also have an entirely incorrect fold. Accuracies of the best model building methods are relatively similar when used optimally [96,106]. Other factors such as template selection and alignment accuracy usually have a larger impact on the model accuracy, especially for models based on less than 40% sequence identity to the templates.

9. MODELING ON A GENOMIC SCALE

Threading and comparative modeling methods have been applied on a genomic scale [105, 107,108]. Domains in approximately one half of all 1,300,000 known protein sequences were modeled with MODPIPE [105,107] and MODELLER [30], and deposited into a comprehensive database of comparative models, MODBASE [9]. The web interface to the database allows flexible querying for fold assignments, sequence-structure alignments, models, and model assessments. An integrated sequence/structure viewer, Chimera [110], allows inspection and analysis of the query results. MODBASE is inter-linked with other applications and databases such that structures and other types of information can be easily used for functional annotation. For example, MODBASE contains binding site predictions for small ligands and a set of predicted interactions between pairs of modeled sequences from the same genome. Other resources associated with MODBASE include a comprehensive database of multiple protein structure alignments (DBALI) as well as web servers for automated comparative modeling with MODPIPE (MODWEB), modeling of loops in protein structures (MODLOOP), and predicting functional consequences of single nucleotide polymorphisms (SNPWEB) [109,111,113].

While the current number of modeled proteins may look impressive given the early stage of structural genomics, usually only one domain per protein is modeled

(on the average, proteins have slightly more than two domains) and two thirds of the models are based on less than 30% sequence identity to the closest template.

10. APPLICATIONS OF COMPARATIVE MODELING TO DRUG DISCOVERY

There is a wide range of applications of protein structure models [5]. For example, high and medium accuracy comparative models frequently are helpful in refining functional predictions that have been based on a sequence match alone because ligand binding is more directly determined by the structure of the binding site than by its sequence. It is often possible to correctly predict features of the target protein that do not occur in the template structure. The size of a ligand may be predicted from the volume of the binding site cleft, and the location of a binding site for a charged ligand can be predicted from a cluster of charged residues on the protein. Fortunately, errors in the functionally important regions in comparative models are many times relatively low because the functional regions, such as active sites, tend to be more conserved in evolution than the rest of the fold. Even low accuracy comparative models may be useful, for example, for assigning the fold of a protein. Fold assignment can be very helpful in drug discovery, because it can shortcut the search for leads by pointing to compounds that have been previously developed for other members of the same family [114,115].

10.1. Comparative models vs experimental structures in virtual screening

The remainder of this review focuses on the use of comparative models for ligand docking [116–118]. It is widely accepted that docking to comparative models is more challenging and less successful than docking to crystallographic structures. However, surprisingly little work has been done to quantify the accuracy of docking to comparative models, to determine in detail why the results are inferior to those obtained with crystal structures, and to improve methods for docking to comparative models. Efforts along these lines, directed at the important kinase and GPCR drug targets, are described in separate sections below.

We begin our discussion with a study that compared the success of docking against ten enzymes, each in three different conformations: holo (ligand bound), apo, and homology modeled [119]. Each enzyme had multiple known inhibitors in the MDDR database, a library of drug-like molecules where each molecule has been annotated by the receptor to which it binds. Success of the docking, carried out with the this group's version of DOCK, was assessed by enrichment: the ability to distinguish known inhibitors from a large set of 'decoys' (~ 100,000 of them in this case), relative to random selection. As might be expected, the holo structures were the best at selecting the known ligands from among the MDDR decoys based on docking score. Unexpectedly, the comparative models, all taken from the MODBASE website without any special preparation, often ranked known ligands among the top-scoring database molecules. In four targets, this enrichment was better than 20-fold over random for top-scoring molecules [119]. In one

case, purine nucleoside phosphorylase, the modeled structure actually performed better than the holo structure. For the comparative model, 25% of the known ligands were found in the top 1.2% of the ranked database, whereas for the holo conformation 2.8% of the ranked list had to be searched before 25% of the ligands were found. Thus, whereas X-ray crystallographic structures remain the first choice in docking, in many cases comparative models seem good enough to highly rank known ligands from among a very large list of possible alternatives.

10.2. Use of comparative models to obtain novel drug leads

Comparative models have been used in conjunction with virtual screening to successfully identify novel inhibitors over the past few years. We briefly review a few of these ‘success stories’ to highlight the potential of this approach. The role of comparative modeling in the design of new kinase inhibitors is discussed separately, below.

A series of papers demonstrate the successful use comparative protein structure models to aid rational drug design against parasites. Comparative models were used for computational docking studies that identified low micromolar nonpeptidic inhibitors of proteases in malaria and the schistosome [53]. Subsequently, further work applied similar methods to develop nanomolar inhibitors of falcipain that are active against chloroquine-resistant strains of malaria [120]. Additionally, comparative models were used to predict new nonpeptide inhibitors of cathepsin L-like cysteine proteases in *L. major* [121]. Sixty-nine compounds were selected by DOCK 3.5 as strong binders to a comparative model of protein cpB, and of these, 21 had experimental IC₅₀ values below 100 μM. Finally, comparative models were used to rationalize ligand binding affinities of cysteine proteases in *E. histolytica* [122]. Specifically, this work provided an explanation for why proteins ACP1 and ACP2 had substrate specificity similar to that of cathepsin B, although their overall structure is more similar to that of cathepsin D.

Fifteen new inhibitors of matriptase have been discovered by docking against its comparative model [123]. The comparative model employed thrombin as the template, sharing only 34% sequence identity with the target sequence. Moreover, some residues in the binding site are significantly different, including a trio of Asp residues in thrombin that are modified to Tyr and Trp in matriptase. Thrombin was chosen as the template, in part, because it prefers substrates with positively charged residues at the P1 position, as does matriptase. The comparative model was constructed using MODELLER and refined with MD simulations in CHARMM. The NCI database was used for virtual screening that targeted the S1 site with the DOCK program. The 2000 best-scoring compounds were manually inspected to identify positively charged ligands (the S1 site is negatively charged), and 69 compounds were experimentally screened for inhibition, identifying 15 inhibitors. One of them, hexamidine, was used as a lead to identify additional compounds selective for matriptase relative to thrombin. Another group has also used similar methods to discover seven new, low-micromolar inhibitors of Bcl-2, using a comparative model based on the NMR solution structure of Bcl-X_L [124].

A novel inhibitor of a retinoic acid receptor by virtual screening using a comparative model [125]. In this case, the target (RAR-α) and template (RAR-γ) are very closely

related; only three residues in the binding site are not conserved. The ICM program was used for virtual screening of ligands from the Available Chemicals Directory, using a hierarchical approach. As with other studies, 300 good-scoring compounds from the virtual screening were manually inspected to choose the final 30 for testing. Two novel agonists were identified, with 50 nanomolar activity.

Novel inhibitors of DHFR in *T. cruzi* (the parasite that causes Chagas' disease) were discovered by docking into a comparative model based on ~50% sequence identity to DHFR in *L. major*, a related parasite [126]. The virtual screening procedure used DOCK for rigid docking of over 50,000 selected compounds from the Cambridge Structural Database. Visual inspection of the top 100 hits was used to select 36 compounds for experimental testing. This work identified several novel scaffolds with micromolar IC₅₀ values. The authors report attempting to use virtual screening results to identify compounds with greater affinity for *T. cruzi* DHFR than human DHFR, but it is not clear how successful they were.

10.3. Comparative models of kinases in virtual screening

Protein kinases have been intensely investigated as drug targets. The large number of kinases in the human genome (~500) is both an asset and a liability for drug development efforts. The catalytic domain of kinases (i.e., the domain that binds ATP and effects phosphorylation of substrates) is well conserved structurally, making it possible to construct comparative models for this domain for many of the kinases in the human genome. On the other hand, the high level of sequence conservation around the ATP binding site—the site most frequently targeted for inhibitor development—raises concerns about selectivity. Drugs that inadvertently inhibit kinases unrelated to the disease state one intends to treat may lead to side effects (although activity against several kinases may be desirable for treating some diseases). Proteins other than kinases can also contain ATP binding sites, of course, although it is not clear whether selectivity across protein families is a problem in practice. Reliable comparative models of kinases can in principle help to address issues of selectivity and aid drug development against the many kinases lacking experimental structures. Work along these lines remains at an early stage. Here we highlight five studies in which kinase comparative models were used in virtual screening applications; two of these studies developed new kinase inhibitors, while the remaining three focused on methodological issues.

A selective inhibitor of human CK2 was discovered by virtual screening [144]. Because no experimental structure of the human protein was available at the time, a comparative model of this kinase based on the structure of CK2 from *Zea mays*, using the WhatIf program [127]. The level of sequence identity between the two proteins is very high: 72% overall, and 82% in the ATP binding site. The crystal structure of human CK2 was subsequently solved, and the C α RMS error of the model was determined to be only 0.92 Å overall, and 0.64 Å in the binding site. DOCK was used to screen a corporate database of 400,000 compounds against the comparative model. As with many other studies, the hit list was subjected to extensive filtering based on a variety of factors including visual inspection. A dozen compounds were tested, yielding several inhibitors with activity at 10 μ M, and one with an IC₅₀ of 80 nM – the most potent inhibitor of CK2

yet reported. Fortuitously, this inhibitor has excellent selectivity, showing much weaker inhibition of other kinases.

In another successful use of kinase comparative models for inhibitor development, was in the virtual screening of a model of CDK4, a member of the important cyclic-dependent kinase class of drug targets (CDKs play a central role in regulation of the cell cycle) [145]. The comparative model was built from the crystal structure of CDK2 in its activated (phosphorylated) form (45% sequence identity). The *de novo* design program LEGEND was then used to predict inhibitors, which were subsequently filtered based on commercial availability. Of 382 tested compounds, 18 had IC₅₀ values better than 500 μM. After several rounds of optimization, one inhibitor had an IC₅₀ of 42 nM. The predicted binding mode of this inhibitor was subsequently supported by a crystal structure of the inhibitor bound to CDK2.

Two recent papers have evaluated the enrichment of known kinase inhibitors (relative to randomly selected drug-like molecules) obtained by virtual screening against kinase comparative models. Construction of a total of 17 comparative models of six kinases, using templates with sequence identity ranging from 30 to 77% was used in the first study [128]. Four of these kinases had crystal structures available for comparison. Known inhibitors for the kinases (ranging from 46 for VEGFR1 to 387 for EGFR) were combined with 32,000 random compounds for the virtual screening, which used the LibDock program [129]. In five of six cases, the known inhibitors were found to be enriched by factors of 4–5 in the top 5% of the docking hits. These results are worse than typical results with kinase crystal structures (although for SRC, the comparative model performed much better than the crystal structure, for reasons that are not entirely clear). This study also compared poses of the docked ligands with crystallographically determined positions, when available, and suggested structural reasons for the difference in enrichment between crystal structures and comparative models.

A further study compared enrichment for models of CDK2 built from several different templates with results for the crystal structure [130]. Comparative models were constructed with MOE, and docking was performed with DOCK. This study concluded that comparative models built from templates with >50% sequence identity provide useful proxies of crystal structures, generating enrichment factors of ~5, similar to the results with the crystal structure. Results for virtual screening against comparative models of factor VIIa were also presented and are similar to those for CDK2.

In a study investigating the differential binding of the drugs Gleevec, purvalanol A, and hymenialdisine to their intended kinase targets and many other kinases, most receptor structures were constructed by comparative modeling [131]. This study represents an early effort toward using comparative models to help assess possible side effects of drugs caused by unintended binding to homologs of the intended target protein.

10.4. GPCR comparative models for drug development

Comparative modeling takes on special importance for the G-protein coupled receptors (GPCRs). This class of membrane proteins has played an enormously important role in drug development; approximately 40% of all drugs target a member of this class. However, they are very difficult to crystallize, and most of the comparative modeling

effort has been based on the atomic-resolution structure of bovine rhodopsin. Comparative modeling methods for GPCRs capable of accuracy sufficient for structure-based drug design would have an enormous impact on drug discovery. Several serious challenges confront this goal. Many targets of interest for drug development share rather low sequence identity (<30%) with rhodopsin. Although the transmembrane helices can frequently be aligned with reasonable certainty (aided by certain highly conserved residues), the extracellular loops are much more divergent in sequence. Finally, model building algorithms typically do not take the membrane environment into account explicitly, although it is not clear whether this approximation is a significant factor for reconstructing the ligand binding sites. Despite these challenges, encouraging early results have been reported for docking into comparative models of GPCRs. In fact, enrichment of known ligands in virtual screening has become an important means of validating GPCR comparative models.

A rather extensive test of docking methods with rhodopsin-based comparative models, using three different docking programs and seven different scoring functions has recently been reported [132]. The comparative modeling protocol is intricate, and includes manual adjustment of sequence alignments, specialized loop search methods for the second extracellular loop, and energy minimization of the model using AMBER. Models were separately prepared for agonists and antagonists; that is, known ligands were manually 'docked' into the binding site in reasonable poses, and the protein structure was again minimized. Several different docking protocols were attempted, and the authors report that the use of a 'consensus' scoring procedure involving three scoring functions provides the best results. Under optimal conditions, the rather elaborate procedures produced encouraging results in cross-docking experiments involving known ligands of the β_2 and D3 receptors, and in enrichment tests using 990 randomly chosen compounds from the ACD.

The ICM flexible docking algorithm could successfully reproduce the conformation of the retinal ligand in rhodopsin and rank this ligand in the top 2% relative to a database of decoy ligands [133]. Encouragingly, the method appears to be robust with respect to entirely deleting the extracellular loop regions (which are difficult to model) and errors in the binding site side chain conformations. GPCR models generated by the MembStruk [134] and PREDICT [135,136] methods, which do not explicitly rely on the rhodopsin structure, also appear to be useful for virtual screening purposes.

10.5. Other uses of comparative models in drug development

Clearly, as the previous discussion shows, comparative models are finding increasing application in virtual ligand screening. However, comparative models have been put to use in many other ways in the context of drug development, generally to obtain qualitative insights to guide inhibitor development. In contrast to the literature on docking to comparative models, the number of papers in this category is quite large, and we aim to provide only a flavor of the many ways in which comparative models have been used.

One common use of comparative models is to rationalize trends in binding affinities among known inhibitors or structure-activity relationships, with an aim of guiding future

lead discovery and optimization efforts. In these studies, docking algorithms are used primarily to generate possible binding modes of known inhibitors in comparative models, providing a structural context for understanding existing data on these inhibitors. Examples include recent studies of the cysteine protease falcipain-3 in malaria, thymidine phosphorylase, thymidine kinase, and androgen receptor [137–140]. Similar studies have also combined comparative modeling and docking to help guide the improvement of the pharmacokinetic properties of inhibitors, rationalize the role of mutations in the development of drug resistance, and understand selectivity of drugs against homologous proteins [141–143].

10.6. Future directions

Although recent reports of successful virtual screening against comparative models are encouraging, such efforts are not yet a routine part of rational drug design efforts. Even the successful efforts appear to rely strongly on visual inspection of the docking results, and it is clear that much work remains to improve the robustness and accuracy of docking against comparative models. Although a number of studies have compared docking against comparative models with docking against crystal structures of the same proteins, little work has been done to compare the accuracy achievable by different approaches to comparative modeling, or to identify the specific structural reasons why comparative models produce less accurate virtual screening results. Among the many issues that deserve consideration are the following:

- The inclusion of co-factors and bound waters in protein receptors is often critical for success of virtual screening; however, co-factors are not routinely included in comparative models.
- The accuracy of comparative models is frequently judged by the C α RMS error, or similar measures of backbone accuracy. For virtual screening, however, the precise positioning of side chains in the binding site is likely to be critical; measures of accuracy for binding sites are needed to help evaluate the suitability of comparative modeling algorithms for constructing models for docking.
- Knowledge of known inhibitors, either for the target protein or the template, can be used to evaluate and improve virtual screening against comparative models. For example, comparative models constructed from ‘holo’ template structures implicitly preserve some information about the ligand-bound receptor conformation.
- Improvement in the accuracy of models produced by comparative modeling will require methods that finely sample protein conformational space using a free energy or scoring function that has sufficient accuracy to distinguish the native structure from the non-native conformations. Despite many years of development of molecular simulation methods, attempts to refine models that are already relatively close to the native structure have met with relatively little success. This failure is likely to be due to inaccuracies in the potential functions used in the simulations, particularly in the treatment of electrostatics and solvation effects. Improvements in sampling strategies may also be necessary. Combination of physical chemistry with the vast amount of

information in known protein structures may provide a route to development of improved potential functions.

11. CONCLUSIONS

High-resolution crystallographic structures becoming available for all human and pathogen proteins and complexes is a very unlikely scenario. The only practical manner of exploring ligand–protein interactions for most systems is to use comparative protein structure models. It is now clear that comparative models, based on as little as 30% sequence identity to known template structures, can be useful. New methods that improve and combine existing modeling and docking techniques to further advance the utility of comparative models will no doubt be developed in the future.

REFERENCES

- [1] S. E. Brenner, *Nat. Struct. Biol.*, 2000, **7**(Suppl.), 967.
- [2] B. Boeckmann, A. Bairoch, R. Apweiler, M. C. Blatter, A. Estreicher, E. Gasteiger, M. J. Martin, K. Michoud, C. O'Donovan, I. Phan, *et al.*, *Nucleic Acids Res.*, 2003, **31**, 365.
- [3] D. A. Benson, I. Karsch-Mizrachi, D. J. Lipman, J. Ostell, B. A. Rapp and L. Wheeler, *Nucleic Acids Res.*, 2002, **30**, 17.
- [4] H. M. Berman, T. Battistuz, T. N. Bhat, W. F. Bluhm, P. E. Bourne, K. Burkhardt, Z. Feng, G. L. Gilliland, L. Iype, S. Jain, *et al.*, *Acta Crystallogr. D.*, 2002, **58**, 899.
- [5] D. Baker and A. Sali, *Science*, 2001, **294**, 93.
- [6] M. A. Marti-Renom, A. Stuart, A. Fiser, R. Sanchez, F. Melo and A. Sali, *Annu. Rev. Biophys. Biomol. Struct.*, 2000, **29**, 291.
- [7] R. Bonneau and D. Baker, *Annu. Rev. Biophys. Biomol. Struct.*, 2001, **30**, 173.
- [8] D. Baker, *Nature*, 2000, **405**, 39.
- [9] U. Pieper, N. Eswar, H. Braberg, M. S. Madhusudhan, F. P. Davis, A. C. Stuart, N. Mirkovic, A. Rossi, M. A. Marti-Renom, A. Fiser, *et al.*, *Nucleic Acids Res.*, 2004, **32**, D217, Database issue, <http://www.salilab.org/modbase/> and <http://www.nysqxc.org/>.
- [10] D. Fischer, A. Elofsson, L. Rychlewski, F. Pazos, A. Valencia, B. Rost, A. R. Ortiz and R. L. Dunbrack, Jr, *Proteins*, 2001, **45** (Suppl. 5), 171.
- [11] P. E. Bourne, *Methods Biochem. Anal.*, 2003, **44**, 501.
- [12] J. M. Bujnicki, A. Elofsson, D. Fischer and L. Rychlewski, *Prot. Sci.*, 2001, **10**, 352.
- [13] V. A. Eylich, M. A. Marti-Renom, D. Przybylski, M. S. Madhusudhan, A. Fiser, F. Pazos, A. Valencia, A. Sali and B. Rost, *Bioinformatics*, 2001, **17**, 1242.
- [14] I.-Y. Y. Koh, V. A. Eylich, M. A. Marti-Renom, D. Przybylski, M. S. Madhusudhan, E. Narayanan, O. Graca, F. Pazos, A. Valencia, A. Sali, *et al.*, *Nucleic Acids Res.*, 2003.
- [15] A. Sali, *Nat. Struct. Biol.*, 1998, **5**, 1029.
- [16] S. K. Burley, S. C. Almo, J. B. Bonanno, M. Capel, M. R. Chance, T. Gaasterland, D. Lin, A. Sali, F. W. Studier and S. Swaminathan, *Nat. Genet.*, 1999, **23**, 151.
- [17] D. Vitkup, E. Melamud, J. Moult and C. Sander, *Nat. Struct. Biol.*, 2001, **8**, 559.
- [18] S. F. Altschul, W. Gish, W. Miller, E. W. Myers and D. J. Lipman, *J. Mol. Biol.*, 1990, **215**, 403.
- [19] W. R. Pearson, *Methods Enzymol.*, 1990, **183**, 63.
- [20] S. F. Altschul, T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller and D. J. Lipman, *Nucleic Acids Res.*, 1997, **25**, 3389.
- [21] M. A. Marti-Renom, M. S. Madhusudhan and A. Sali, *Prot. Sci.*, 2004, **13**, 1071.
- [22] R. Karchin, M. Cline, Y. Mandel-Gutfreund and M. Karplus, *Proteins*, 2003, **51**, 504.

- [23] A. E. Torda, *Curr. Opin. Struct. Biol.*, 1997, **7**, 200.
- [24] B. John and A. Sali, *Nucleic Acids Res.*, 2003, **31**, 3982–3992.
- [25] W. J. Browne, A. C. T. North, D. C. Phillips, K. Brew, T. C. Vanaman and R. C. Hill, *J. Mol. Biol.*, 1969, **42**, 65.
- [26] J. Greer, *J. Mol. Biol.*, 1981, **153**, 1027.
- [27] T. L. Blundell, B. L. Sibanda, M. J. Sternberg and J. M. Thornton, *Nature*, 1987, **326**, 347.
- [28] M. Levitt, *J. Mol. Biol.*, 1992, **226**, 507.
- [29] T. F. Havel and M. E. Snow, *J. Mol. Biol.*, 1991, **217**, 1.
- [30] A. Sali and T. L. Blundell, *J. Mol. Biol.*, 1993, **234**, 779.
- [31] A. Kolinski, M. R. Betancourt, D. Kihara, P. Rotkiewicz and J. Skolnick, *Proteins*, 2001, **44**, 133.
- [32] W. Kabsch and C. Sander, *Proc. Natl. Acad. Sci. USA*, 1984, **81**, 1075.
- [33] M. Mezei, *Prot. Eng.*, 1998, **11**, 411.
- [34] A. Fiser, R. K. Do and A. Sali, *Prot. Sci.*, 2000, **9**, 1753, <http://www.salilab.org/modeller>.
- [35] M. P. Jacobson, D. L. Pincus, C. S. Rapp, T. J. Day, B. Honig, D. E. Shaw and R. A. Friesner, *Proteins*, 2004, **55**, 351.
- [36] T. A. Jones and S. Thirup, *EMBO J.*, 1986, **5**, 819.
- [37] C. Chothia and M. Lesk, *J. Mol. Biol.*, 1987, **196**, 901.
- [38] J. Moulton and M. N. James, *Proteins*, 1986, **1**, 146.
- [39] R. E. Bruccoleri and M. Karplus, *Biopolymers*, 1987, **26**, 137.
- [40] P. S. Shenkin, D. L. Yarmush, R. M. Fine, H. J. Wang and C. Levinthal, *Biopolymers*, 1987, **26**, 2053.
- [41] H. W. van Vlijmen and M. Karplus, *J. Mol. Biol.*, 1997, **267**, 975.
- [42] C. M. Deane and T. L. Blundell, *Prot. Sci.*, 2001, **10**, 599.
- [43] B. L. Sibanda, T. L. Blundell and J. M. Thornton, *J. Mol. Biol.*, 1989, **206**, 759.
- [44] C. Chothia, A. M. Lesk, A. Tramontano, M. Levitt, S. J. Smith-Gill, G. Air, S. Sheriff, E. A. Padlan, D. Davies, W. R. Tulip, *et al.*, *Nature*, 1989, **342**, 877.
- [45] C. S. Ring, D. G. Kneller, R. Langridge and F. E. Cohen, *J. Mol. Biol.*, 1992, **224**, 685.
- [46] B. Oliva, P. A. Bates, E. Querol, F. X. Aviles and M. J. Sternberg, *J. Mol. Biol.*, 1997, **266**, 814.
- [47] S. D. Rufino, L. E. Donate, L. H. Canard and T. L. Blundell, *J. Mol. Biol.*, 1997, **267**, 352.
- [48] K. Fidelis, P. S. Stern, D. Bacon and J. Moulton, *Prot. Eng.*, 1994, **7**, 953.
- [49] U. Lessel and D. Schomburg, *Prot. Eng.*, 1994, **7**, 1175–1187.
- [50] M. Claessens, E. Van Cutsem, I. Lasters and S. Wodak, *Prot. Eng.*, 1989, **2**, 335.
- [51] R. M. Fine, H. Wang, P. S. Shenkin, D. L. Yarmush and C. Levinthal, *Proteins*, 1986, **1**, 342.
- [52] R. E. Bruccoleri and M. Karplus, *Biopolymers*, 1990, **29**, 1847.
- [53] C. S. Ring, E. Sun, J. H. McKerrow, G. K. Lee, P. J. Rosenthal, I. D. Kuntz and F. E. Cohen, *Proc. Natl. Acad. Sci. USA*, 1993, **90**, 3583.
- [54] J. Higo, V. Collura and J. Garnier, *Biopolymers*, 1992, **32**, 33.
- [55] V. Collura, J. Higo and J. Garnier, *Prot. Sci.*, 1993, **2**, 1502.
- [56] R. Abagyan and M. Totrov, *J. Mol. Biol.*, 1994, **235**, 983.
- [57] Q. Zheng, R. Rosenfeld, S. Vajda and C. DeLisi, *Prot. Sci.*, 1993, **2**, 1242.
- [58] P. Koehl and M. Delarue, *Nat. Struct. Biol.*, 1995, **2**, 163.
- [59] R. Samudrala and J. Moulton, *J. Mol. Biol.*, 1998, **279**, 287.
- [60] Z. Xiang, C. S. Soto and B. Honig, *Proc. Natl. Acad. Sci. USA*, 2002, **99**, 7432–7437.
- [61] A. K. Felts, E. Gallicchio, A. Wallqvist and R. M. Levy, *Proteins*, 2002, **48**, 404.
- [62] P. I. de Bakker, M. A. DePristo, D. F. Burke and T. L. Blundell, *Proteins*, 2003, **51**, 21.
- [63] M. A. DePristo, P. I. de Bakker, S. C. Lovell and T. L. Blundell, *Proteins*, 2003, **51**, 41.
- [64] M. P. Jacobson, D. L. Pincus, C. S. Rapp, T. J. F. Day, B. Honig, D. E. Shaw and R. A. Friesner, *Proteins*, 2004, **55**, 351.
- [65] C. Chothia, A. M. Lesk, M. Levitt, A. G. Amit, R. A. Mariuzza, S. E. Phillips and R. J. Poljak, *Science*, 1986, **233**, 755.
- [66] J. Janin and C. Chothia, *Biochemistry*, 1978, **17**, 2943.
- [67] J. W. Ponder and F. M. Richards, *J. Mol. Biol.*, 1987, **193**, 775.
- [68] P. Tuffery, C. Etchebest, S. Hazout and R. Lavery, *J. Biomol. Struct. Dyn.*, 1991, **8**, 1267.

- [69] R. L. Dunbrack and M. Karplus, *J. Mol. Biol.*, 1993, **230**, 543.
- [70] R. L. Dunbrack, Jr and F. E. Cohen, *Prot. Sci.*, 1997, **6**, 1661.
- [71] J. Mendes, A. M. Baptista, M. A. Carrondo and C. M. Soares, *Proteins*, 1999, **37**, 530.
- [72] Z. Xiang and B. Honig, *J. Mol. Biol.*, 2001, **311**, 421–430.
- [73] J. R. Desjarlais and T. M. Handel, *J. Mol. Biol.*, 1999, **290**, 305.
- [74] V. De Filippis, C. Sander and G. Vriend, *Prot. Eng.*, 1994, **7**, 1203.
- [75] S. Y. Chung and S. Subbiah, *Pac. Symp. Biocomput.*, 1996, 126.
- [76] D. Cregut, J. P. Liautard and L. Chiche, *Prot. Eng.*, 1994, **7**, 1333.
- [77] A. A. Canutescu, A. A. Shelenkov and R. L. Dunbrack, Jr, *Prot. Sci.*, 2003, **12**, 2001.
- [78] F. Eisenmenger, P. Argos and R. Abagyan, *J. Mol. Biol.*, 1993, **231**, 849.
- [79] G. M. Lee, A. Varma and B. O. Palsson, *Biotechnol. Prog.*, 1991, **7**, 72.
- [80] L. Holm and C. Sander, *Proteins*, 1992, **14**, 213.
- [81] I. Lasters and J. Desmet, *Prot. Eng.*, 1993, **6**, 717.
- [82] L. L. Looger and H. W. Hellinga, *J. Mol. Biol.*, 2001, **307**, 429.
- [83] J. K. Hwang and W. F. Liao, *Prot. Eng.*, 1995, **8**, 363.
- [84] P. Koehl and M. Delarue, *J. Mol. Biol.*, 1994, **239**, 249.
- [85] M. J. Bower, F. E. Cohen and R. L. Dunbrack, Jr, *J. Mol. Biol.*, 1997, **267**, 1268.
- [86] R. J. Petrella, T. Lazaridis and M. Karplus, *Fold. Des.*, 1998, **3**, 353.
- [87] M. P. Jacobson, G. A. Kaminski, R. A. Friesner and C. S. Rapp, *J. Phys. Chem. B*, 2002, **106**, 11673.
- [88] S. Liang and N. V. Grishin, *Prot. Sci.*, 2002, **11**, 322.
- [89] A. D. MacKerell, Jr, D. Bashford, M. Bellott, R. L. Dunbrack, Jr, J. D. Evanseck, M. J. Field, S. Fischer, J. Gao, H. Guo, S. Ha, *et al.*, *J. Phys. Chem. B*, 1998, **102**, 3586.
- [90] A. Sali and J. P. Overington, *Prot. Sci.*, 1994, **3**, 1582–1596.
- [91] C. S. Rapp and R. A. Friesner, *Proteins*, 1999, **35**, 173.
- [92] A. Fiser, M. Feig, C. L. Brooks, III and A. Sali, *Acc. Chem. Res.*, 2002, **35**, 413.
- [93] M. P. Jacobson, R. A. Friesner, Z. X. Xiang and B. Honig, *J. Mol. Biol.*, 2002, **320**, 597.
- [94] V. Hornak and C. Simmerling, *Proteins*, 2003, **51**, 577.
- [95] J. Moult, *Curr. Opin. Biotechnol.*, 1996, **7**, 422.
- [96] P. Koehl and M. Levitt, *Nat. Struct. Biol.*, 1999, **6**, 108.
- [97] B. N. Dominy and C. L. Brooks, *J. Comp. Chem.*, 2002, **23**, 147.
- [98] H. Li, R. Tejero, D. Monleon, D. BassolinoKlimas, C. AbateShen, R. E. Bruccoleri and G. T. Montelione, *Prot. Sci.*, 1997, **6**, 956.
- [99] J. A. Flohil, G. Vriend and H. J. C. Berendsen, *Proteins*, 2002, **48**, 593.
- [100] W. L. Jorgensen and J. Tiradorives, *J. Am. Chem. Soc.*, 1988, **110**, 1666.
- [101] G. A. Kaminski, R. A. Friesner, J. Tirado-Rives and W. L. Jorgensen, *J. Phys. Chem. B*, 2001, **105**, 6474.
- [102] A. Ghosh, C. S. Rapp and R. A. Friesner, *J. Phys. Chem. B*, 1998, **102**, 10983.
- [103] E. Gallicchio, L. Y. Zhang and R. M. Levy, *J. Comp. Chem.*, 2002, **23**, 517.
- [104] X. Li, M. P. Jacobson and R. A. Friesner, *Proteins*, 2004.
- [105] R. Sanchez and A. Sali, *Proc. Natl Acad. Sci. USA*, 1998, **95**, 13597.
- [106] M. A. Marti-Renom, M. S. Madhusudhan, A. Fiser, B. Rost and A. Sali, *Structure*, 2002, **10**, 435.
- [107] D. Fischer and D. Eisenberg, *Proc. Natl Acad. Sci. USA*, 1997, **94**, 11929.
- [108] N. Guex, A. Diemand and M. C. Peitsch, *Trends Biochem. Sci.*, 1999, **24**, 364.
- [109] N. Eswar, B. John, N. Mirkovic, A. Fiser, V. A. Ilyin, U. Pieper, A. C. Stuart, M. A. Marti-Renom, M. S. Madhusudhan, B. Yerkovich, *et al.*, *Nucleic Acids Res.*, 2003, **31**, 3375, <http://www.salilab.org/modweb>.
- [110] C. C. Huang, W. R. Novak, P. C. Babbitt, A. I. Jewett, T. E. Ferrin and T. E. Klein, *Pac. Symp. Biocomput.*, 2000, 230.
- [111] M. A. Marti-Renom, V. A. Ilyin and A. Sali, *Bioinformatics*, 2001, **17**, 746, <http://www.salilab.org/dbali>.
- Q1 [112] A. Fiser and A. Sali, *Bioinformatics*, 2003, **19**, 2500.
- [113] N. Mirkovic, M. A. Marti-Renom, A. Sali and A. N. A. Monteiro, *Cancer Res.*, 2004, **64**, 3790.
- [114] R. K. Gordon, K. Ginalski, W. R. Rudnicki, L. Rychlewski, M. C. Pankaskie, J. M. Bujnicki and P. K. Chiang, *Eur. J. Biochem.*, 2003, **270**, 3507.

- [115] M. von Grothuss, L. S. Wyrwicz and L. Rychlewski, *Cell*, 2003, **113**, 701.
- [116] A. Schafferhans and G. Klebe, *J. Mol. Biol.*, 2001, **307**, 407–427.
- [117] A. Evers, H. Gohlke and G. Klebe, *J. Mol. Biol.*, 2003, **334**, 327–345.
- [118] A. Evers and G. Klebe, *Angew Chem. Int. Ed. Engl.*, 2004, **43**, 248–251.
- [119] S. L. McGovern and B. K. Shoichet, *J. Med. Chem.*, 2003, **46**, 2895.
- [120] R. Li, X. Chen, B. Gong, P. M. Selzer, Z. Li, E. Davidson, G. Kurzban, R. E. Miller, E. O. Nuzum, J. H. McKerrow, *et al.*, *Bioorg. Med. Chem. Lett.*, 1996, **4**, 1421.
- [121] P. M. Selzer, X. Chen, V. J. Chan, M. Cheng, G. L. Kenyon, I. D. Kuntz, J. A. Sakanari, F. E. Cohen and J. H. McKerrow, *Exp. Parasitol.*, 1997, **87**, 212.
- [122] X. Que, L. S. Brinen, P. Perkins, S. Herdman, K. Hirata, B. E. Torian, H. Rubin, J. H. McKerrow and S. L. Reed, *Mol. Biochem. Parasitol.*, 2002, **119**, 23.
- [123] I. J. Enyedy, S. L. Lee, A. H. Kuo, R. B. Dickson, C. Y. Lin and S. Wang, *J. Med. Chem.*, 2001, **44**, 1349.
- [124] I. J. Enyedy, Y. Ling, K. Nacro, Y. Tomita, X. Wu, Y. Cao, R. Guo, B. Li, X. Zhu, Y. Huang, *et al.*, *J. Med. Chem.*, 2001, **44**, 4313.
- [125] M. Schapira, B. M. Raaka, H. H. Samuels and R. Abagyan, *BMC Struct. Biol.*, 2001, **1**, 1.
- [126] F. Zuccotto, M. Zvelebil, R. Brun, S. F. Chowdhury, R. Di Lucrezia, I. Leal, L. Maes, L. M. Ruiz-Perez, D. Gonzalez Pacanowska and I. H. Gilbert, *Eur. J. Med. Chem.*, 2001, **36**.
- [127] G. Vriend, *J. Mol. Graph.*, 1990, **8**, 52.
- [128] D. J. Diller and R. Li, *J. Med. Chem.*, 2003, **46**, 4638.
- [129] D. J. Diller and K. M. Merz, *Proteins*, 2001, **43**, 113.
- [130] C. Oshiro, E. K. Bradley, J. Eksterowicz, E. Evensen, M. L. Lamb, J. K. Lancot, S. Putta, R. Stanton and P. D. Grootenhuis, *J. Med. Chem.*, 2004, **47**, 764.
- [131] W. M. Rokey and A. H. Elcock, *Proteins*, 2002, **48**, 664.
- [132] C. Bissantz, P. Bernard, M. Hibert and D. Rognan, *Proteins*, 2003, **50**, 5.
- [133] C. N. Cavasotto, A. J. Orry and R. A. Abagyan, *Proteins*, 2003, **51**, 423.
- [134] N. Vaidehi, W. B. Floriano, R. Trabanino, S. E. Hall, P. Freddolino, E. J. Choi, G. Zamanakos and W. A. Goddard, III, *Proc. Natl Acad. Sci. USA*, 2002, **99**, 12622.
- [135] S. Shacham, M. Topf, N. Avisar, F. Glaser, Y. Marantz, S. Bar-Haim, S. Noiman, Z. Naor and O. M. Becker, *Med. Res. Rev.*, 2001, **21**, 472.
- [136] O. M. Becker, S. Shacham, Y. Marantz and S. Noiman, *Curr. Opin. Drug. Discov. Devel.*, 2003, **6**, 353.
- [137] Y. A. Sabnis, P. V. Desai, P. J. Rosenthal and M. A. Avery, *Prot. Sci.*, 2003, **12**, 501.
- [138] M. L. Price, W. C. Guida, T. E. Jackson, J. A. Nydick, P. L. Gladstone, J. C. Juarez, F. Donate and R. J. Ternansky, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 107.
- [139] L. Spadola, E. Novellino, G. Folkers and L. Scapozza, *Eur. J. Med. Chem.*, 2003, **38**, 413.
- [140] C. A. Marhefka, B. M. Moore, T. C. Bishop, II, L. Kirkovsky, A. Mukherjee, J. T. Dalton and D. D. Miller, *J. Med. Chem.*, 2001, **44**, 1729.
- [141] M. H. Rabinowitz, R. C. Andrews, J. D. Becherer, D. M. Bickett, D. G. Bubacz, J. G. Conway, D. J. Cowan, M. Gaul, K. Glennon, M. H. Lambert, *et al.*, *J. Med. Chem.*, 2001, **44**, 4252.
- [142] R. T. Delfino, O. A. Santos-Filho and J. D. Figueroa-Villar, *Biophys. Chem.*, 2002, **98**, 287.
- [143] E. A. Salter, A. Wierzbicki, G. Sperl and W. J. Thompson, *Int. J. Quantum Chem.*, 2004, **96**, 402.
- [144] E. Vangrevelinghe, K. Zimmermann, J. Schoepfer, R. Portmann, D. Fabbro and P. Furet, *J. Med. Chem.*, 2003, **46**, 2656.
- [145] T. Honma, K. Hayashi, T. Aoyama, N. Hashimoto, T. Machida, K. Fukasawa, T. Iwama, C. Ikeura, M. Ikuta, I. Suzuki-Takahashi, Y. Iwasawa, T. Hayama, S. Nishimura and H. Morishima, *J. Med. Chem.*, 2001, **44**, 4628.
- [146] http://www.francisco.compbio.ucsf.edu/~jacobson/plop_overview.htm.
- [147] http://www.salilab.org/bioinformatics_resources.shtml.